NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, Price Target & More

$22.19 -0.23 (-1.03 %)
(As of 04/23/2018 01:49 AM ET)
Previous Close$22.19
Today's Range$21.93 - $22.44
52-Week Range$16.80 - $33.81
Volume19,139 shs
Average Volume97,406 shs
Market Capitalization$605.43 million
P/E Ratio-7.84
Dividend YieldN/A
BetaN/A

About Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals logoRhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company's lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280

Debt

Debt-to-Equity RatioN/A
Current Ratio22.42%
Quick Ratio22.42%

Price-To-Earnings

Trailing P/E Ratio-7.84
Forward P/E Ratio-9.32
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.31 per share
Price / Book4.18

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees26
Outstanding Shares27,280,000

How to Become a New Pot Stock Millionaire

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals (NASDAQ:RYTM) posted its earnings results on Monday, March, 12th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.14. View Rhythm Pharmaceuticals' Earnings History.

What price target have analysts set for RYTM?

4 equities research analysts have issued twelve-month price targets for Rhythm Pharmaceuticals' shares. Their forecasts range from $23.00 to $40.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $31.25 in the next twelve months. View Analyst Ratings for Rhythm Pharmaceuticals.

What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
  • 1. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018)
  • 2. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017)

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a drop in short interest in March. As of March 29th, there was short interest totalling 769,212 shares, a drop of 27.3% from the March 15th total of 1,058,717 shares. Based on an average daily volume of 101,017 shares, the days-to-cover ratio is currently 7.6 days. Approximately 6.3% of the company's stock are short sold.

Who are some of Rhythm Pharmaceuticals' key competitors?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the folowing people:
  • David P. Meeker M.D., Chairman of the Board (Age 63)
  • Keith Gottesdiener M.D., President, Chief Executive Officer, Director (Age 63)
  • Hunter C. Smith, Chief Financial Officer, Treasurer (Age 49)
  • Lex H.T. Van der Ploeg Ph.D., Chief Scientific Officer (Age 63)
  • Nithya Desikan, Chief Commercial Officer (Age 38)
  • Fred T. Fiedorek M.D., Chief Medical Officer (Age 62)
  • Neil Exter, Independent Director (Age 58)
  • Todd Foley, Independent Director (Age 45)
  • Christophe R. Jean, Independent Director (Age 61)
  • Edward T. Mathers, Independent Director (Age 57)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

When did Rhythm Pharmaceuticals' lock-up period expire?

Rhythm Pharmaceuticals' lock-up period expired on Tuesday, April 3rd. Rhythm Pharmaceuticals had issued 7,050,000 shares in its IPO on October 5th. The total size of the offering was $119,850,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

News headlines about RYTM stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a daily sentiment score of 0.05 on Accern's scale. They also gave media stories about the company an impact score of 46.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $22.19.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $605.43 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]


MarketBeat Community Rating for Rhythm Pharmaceuticals (RYTM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Rhythm Pharmaceuticals in the last 12 months. Their average twelve-month price target is $31.25, suggesting that the stock has a possible upside of 40.83%. The high price target for RYTM is $40.00 and the low price target for RYTM is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.752.752.75N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.25$31.25$31.25N/A
Price Target Upside: 40.83% upside13.18% upside22.74% upsideN/A

Rhythm Pharmaceuticals (NASDAQ:RYTM) Consensus Price Target History

Price Target History for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/26/2018Needham & Company LLCReiterated RatingBuy$32.00HighView Rating Details
11/14/2017CowenReiterated RatingBuy$40.00N/AView Rating Details
10/30/2017Morgan StanleyInitiated CoverageEqual Weight$23.00N/AView Rating Details
10/30/2017Bank of AmericaInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings History and Estimates Chart

Earnings by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.38 EPS
Next Year EPS Consensus Estimate: $-3.37 EPS

Rhythm Pharmaceuticals (NASDAQ RYTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.55)($0.41)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.3970)($1.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rhythm Pharmaceuticals (NASDAQ:RYTM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 89.91%
Insider Trading History for Rhythm Pharmaceuticals (NASDAQ:RYTM)
Institutional Ownership by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals (NASDAQ RYTM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/10/2017David P MeekerDirectorBuy25,000$17.00$425,000.00View SEC Filing  
10/10/2017James E FlynnInsiderBuy355,000$17.00$6,035,000.00View SEC Filing  
10/10/2017S.A. IpsenMajor ShareholderBuy20,000$17.00$340,000.00View SEC Filing  
10/5/2017Bros. Advisors Lp BakerInsiderBuy885,000$17.00$15,045,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rhythm Pharmaceuticals (NASDAQ RYTM) News Headlines

Source:
DateHeadline
-$0.45 EPS Expected for Rhythm Pharmaceuticals (RYTM) This Quarter-$0.45 EPS Expected for Rhythm Pharmaceuticals (RYTM) This Quarter
www.americanbankingnews.com - April 22 at 9:10 PM
NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine ConferenceNeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference
www.prnewswire.com - April 20 at 10:11 AM
Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, CoConsolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co
www.nasdaq.com - April 20 at 10:11 AM
Rhythm Pharmaceuticals (RYTM) Short Interest Down 27.3% in MarchRhythm Pharmaceuticals (RYTM) Short Interest Down 27.3% in March
www.americanbankingnews.com - April 15 at 2:01 AM
Rhythm Pharmaceuticals Diversifies As A Major Catalyst ApproachesRhythm Pharmaceuticals Diversifies As A Major Catalyst Approaches
seekingalpha.com - April 9 at 4:02 PM
 Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals (RYTM) Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - April 9 at 5:34 AM
BidaskClub Upgrades Rhythm Pharmaceuticals (RYTM) to HoldBidaskClub Upgrades Rhythm Pharmaceuticals (RYTM) to Hold
www.americanbankingnews.com - April 6 at 10:49 AM
Rhythm Pharmaceuticals Inc (RYTM) Expected to Post Earnings of -$0.44 Per ShareRhythm Pharmaceuticals Inc (RYTM) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - April 5 at 11:12 PM
Rhythm Pharmaceuticals (RYTM) Now Covered by Analysts at CowenRhythm Pharmaceuticals (RYTM) Now Covered by Analysts at Cowen
www.americanbankingnews.com - April 4 at 2:58 PM
Rhythm Pharmaceuticals (RYTM) Announces Licensing Agreement with Takeda for Development and Commercialization of Preclinical Treatment for PWSRhythm Pharmaceuticals (RYTM) Announces Licensing Agreement with Takeda for Development and Commercialization of Preclinical Treatment for PWS
www.streetinsider.com - April 2 at 4:05 PM
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi SyndromeRhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
finance.yahoo.com - April 2 at 4:05 PM
Rhythm Pharmaceuticals (RYTM) Stock Rating Lowered by BidaskClubRhythm Pharmaceuticals (RYTM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 9:16 PM
Rhythm Pharmaceuticals Incs Lock-Up Period To End  on April 3rd (NASDAQ:RYTM)Rhythm Pharmaceuticals Inc's Lock-Up Period To End on April 3rd (NASDAQ:RYTM)
www.americanbankingnews.com - March 27 at 1:02 AM
Rhythm Pharmaceuticals (RYTM) Upgraded to "Hold" by BidaskClubRhythm Pharmaceuticals (RYTM) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 26 at 10:58 PM
D.C. drug company faces a new generics threatD.C. drug company faces a new generics threat
www.bizjournals.com - March 26 at 3:57 PM
 Rhythm Pharmaceuticals Inc (RYTM) Receives Consensus Recommendation of "Buy" from Brokerages Rhythm Pharmaceuticals Inc (RYTM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 7:24 PM
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
finance.yahoo.com - March 20 at 10:09 AM
Rhythm Pharmaceuticals (RYTM) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowRhythm Pharmaceuticals (RYTM) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 17 at 10:16 AM
Rhythm Pharmaceuticals (RYTM) Stock Rating Upgraded by BidaskClubRhythm Pharmaceuticals (RYTM) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 14 at 6:39 PM
Rhythm Pharmaceuticals (RYTM) Announces Quarterly  Earnings ResultsRhythm Pharmaceuticals (RYTM) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:56 AM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 4:58 PM
Diurnal Selects Worldwide Clinical Trials as Preferred CRO ProviderDiurnal Selects Worldwide Clinical Trials as Preferred CRO Provider
www.bizjournals.com - March 12 at 9:58 AM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Target Price by BrokeragesZacks: Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 9 at 1:27 AM
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in MarchRhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March
finance.yahoo.com - March 7 at 4:44 PM
Rhythm Pharmaceuticals Inc (RYTM) Short Interest UpdateRhythm Pharmaceuticals Inc (RYTM) Short Interest Update
www.americanbankingnews.com - March 3 at 3:26 AM
Rhythm Pharmaceuticals Inc (RYTM) Expected to Announce Earnings of -$0.55 Per ShareRhythm Pharmaceuticals Inc (RYTM) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - March 2 at 7:16 PM
Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (RYTM)Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - February 26 at 4:20 PM
Rhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at BidaskClubRhythm Pharmaceuticals (RYTM) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 25 at 4:18 PM
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Announce ($0.55) Earnings Per Share
www.americanbankingnews.com - February 22 at 5:10 AM
 Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages Rhythm Pharmaceuticals Inc (RYTM) Given $31.25 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
 Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS
www.americanbankingnews.com - February 14 at 3:18 AM
Rhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClubRhythm Pharmaceuticals (RYTM) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 4 at 6:22 AM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from AnalystsZacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 2 at 7:22 PM
Rhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClubRhythm Pharmaceuticals (RYTM) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 29 at 10:42 PM
Analysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per ShareAnalysts Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post ($0.55) Earnings Per Share
www.americanbankingnews.com - January 25 at 11:41 AM
Critical Analysis: Rhythm Pharmaceuticals (RYTM) versus The CompetitionCritical Analysis: Rhythm Pharmaceuticals (RYTM) versus The Competition
www.americanbankingnews.com - January 10 at 11:14 PM
Zacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Recommendation of "Buy" from AnalystsZacks: Rhythm Pharmaceuticals Inc (RYTM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 9:46 PM
WuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of ObesityWuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of Obesity
finance.yahoo.com - January 9 at 6:11 PM
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of ObesityRhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
finance.yahoo.com - January 4 at 8:49 AM
Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by AnalystsZacks: Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 2 at 8:02 AM
BidaskClub Downgrades Rhythm Pharmaceuticals (RYTM) to HoldBidaskClub Downgrades Rhythm Pharmaceuticals (RYTM) to Hold
www.americanbankingnews.com - December 29 at 6:32 AM
Zacks: Rhythm Pharmaceuticals, Inc. (RYTM) Receives Average Recommendation of "Buy" from BrokeragesZacks: Rhythm Pharmaceuticals, Inc. (RYTM) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 5:52 AM
 Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM) Brokerages Set $31.25 Target Price for Rhythm Pharmaceuticals, Inc. (RYTM)
www.americanbankingnews.com - November 30 at 3:12 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Announces  Earnings ResultsRhythm Pharmaceuticals, Inc. (RYTM) Announces Earnings Results
www.americanbankingnews.com - November 15 at 1:03 PM
 Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts Rhythm Pharmaceuticals, Inc. (RYTM) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 15 at 9:47 AM
General Electric Cuts 2018 EPS Target, Slashes Dividend - Presented by: The Aol. On NetworkGeneral Electric Cuts 2018 EPS Target, Slashes Dividend - Presented by: The Aol. On Network
www.nasdaq.com - November 15 at 7:54 AM
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial ResultsRhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 7:54 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLCRhythm Pharmaceuticals, Inc. (RYTM) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - November 14 at 10:26 PM
Rhythm Pharmaceuticals, Inc. (RYTM) Given "Buy" Rating at Cowen and CompanyRhythm Pharmaceuticals, Inc. (RYTM) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - November 14 at 10:26 PM
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management TeamTorque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
finance.yahoo.com - November 14 at 7:32 AM

SEC Filings

Rhythm Pharmaceuticals (NASDAQ:RYTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rhythm Pharmaceuticals (NASDAQ:RYTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rhythm Pharmaceuticals (NASDAQ RYTM) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.